Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
Target enrollment complete in Phase 1b trial of GT-02287 - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
Target enrollment complete in Phase 1b trial of GT-02287
Parkinson’s News Today
Jul 07, 2025
Target enrollment complete in Phase 1b trial of GT-02287
Related Posts
Post navigation
Previous Post
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations
Next Post
Gain Therapeutics announces pricing of $7M public offering
Latest Articles
Clear Filters
July 1, 2026
Parkinson’s pipeline pushes beyond dopamine
https://www.biocentury.com/article/659501/parkinson-s-pipeline-pushes-beyond-dopamine?utm_term=profiles.biocentury.com
Read More
June 30, 2026
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com
https://in.investing.com/news/stock-market-news/gain-therapeutics-stock-surges-on-fda-clearance-for-parkinsons-drug-93CH-5475234
Read More
June 11, 2026
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
https://european-biotechnology.com/latest-news/scenic-biotech-joins-michael-j-fox-lrrk2-consortium-with-a-novel-lysosomal-bet-on-parkinsons/
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles